Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
CAMBRIDGE, Mass., April 07, 2026 -- Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. Company presentations are not planned at the Symposium.
During meetings, management will discuss its commercial products, and data and other information shared during Akebia’s recent R&D Day that showcased its robust pipeline of clinical stage kidney disease programs.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin ETFs hit the longest inflow streak of the year in bullish setup for a major recovery
Fed to announce last rate decision before new leadership

Trump Treasury is asking Americans to help it pay US national debt via donations from personal wealth
Iran Claims Strong Oil Cards Ahead of Peak Gasoline Demand Season in the US
